Merck: FDA grants Breakthrough Therapy designation to sacituzumab tirumotecan
Merck (MRK) announced that the U.S. FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for the treatment of patients with advanced or metastatic nonsquamous non-small cell ...
Cure Today23 小时
FDA Grants Breakthrough Therapy Designation to Sac-TMT for Some with NSCLC
The FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for patients with advanced or metastatic ...
marketinference23 小时
Janux Therapeutics Reports Positive Clinical Data
Janux Therapeutics' pipeline includes janx007, a tumor-activated T cell engager (TRACT) that targets prostate-specific ...
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $43.33 Average PT from Brokerages
Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX – Get Free Report) have received an average rating of “Buy” from the six ...
Janux Therapeutics (NASDAQ:JANX) Given Outperform Rating at William Blair
William Blair restated their outperform rating on shares of Janux Therapeutics (NASDAQ:JANX – Free Report) in a research note ...
Morningstar22 小时
Fidelity Growth Company Fund
He grapples with the strategy’s heft by crafting a portfolio that invests broadly across the growth spectrum—including in maturing mega-cap stocks and faster-growing companies with slimmer cur ...